Chemomab Therapeutics Ltd - ADR Stock

$1.20

1.64% yesterday

Nasdaq, Jun 13, 10:18 pm CET

ISIN

US16385C1045

Symbol

CMMB

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Chemomab Therapeutics Ltd - ADR Stock price

$1.20

-21.84 94.79% 5Y

Nasdaq, Closing price Fri, Jun 13 2025

-0.02 1.64%

ISIN

US16385C1045

Symbol

CMMB

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$23.01m
Enterprise Value	$12.45m
P/E (TTM) P/E ratio	negative
P/B ratio (TTM) P/B ratio	43.64
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-14.18m
Cash position	$10.56m
EPS (TTM) EPS	$-0.04
P/E forward	negative
Short interest	0.35%

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Get Started for Free Today

Chemomab Therapeutics Ltd - ADR Stock Analysis

Unlock Scores for Free

??

2 Analysts have issued a Chemomab Therapeutics Ltd - ADR forecast:

2x Buy

100%

More details on Analyst Estimates Including Price Targets

2 Analysts have issued a Chemomab Therapeutics Ltd - ADR forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Chemomab Therapeutics Ltd - ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	3.51 3.51	40% 40% -
- Research and Development Expense	11 11	27% 27% -
EBITDA	- -	- -
- Depreciation and Amortization	- -	- -
EBIT (Operating Income) EBIT	-14 -14	31% 31% -
Net Profit	-13 -13	31% 31% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Chemomab Therapeutics Ltd - ADR Stock News

Neutral

GlobeNewsWire

●

3 days ago

Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis

—Achieves FDA Alignment on CMC and Non-Clinical Toxicology Regulatory Path for Nebokitug in PSC— —Preparations for the Nebokitug PSC Phase 3 Clinical Trial Advance as Discussions with Potential Strategic Partners Continue— TEL AVIV, Israel, June 11, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd., (Nasdaq: CMMB), a clinical stage biotechnology company developing innovative therapeutics for ...

Neutral

GlobeNewsWire

●

11 days ago

Chemomab Announces New Patent Awards for Its First-in-Class Agent Nebokitug that is Positioned to Potentially Become the First Approved Drug for Primary Sclerosing Cholangitis

—New Patent s Covering Use of Nebokitug for the Treatment of Liver Diseases including Primary Sclerosing Cholangitis Issued in China and Russia Providing Coverage Up T o 2041 — —Further Ex pands Protections Provided by Nebokitug 's Composition of Matter and Methods and Use Patents Issued in the U.S., Europe, Japan and A dditional Key Territories— TEL AVIV, Israel, June 03, 2025 (GLOBE NEWSWIRE)...

Neutral

GlobeNewsWire

●

about one month ago

Chemomab Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update

— Reported Positive 48-Week Data from SPRING Trial — Nebokitug Treatment in PSC P atients with M oderate/ A dvanced D isease R esulted in C ontinued I mprovements across K ey B iomarkers of Li ver I njury, I nflammation and Fi brosis — — Align ed with FDA on Pathway to Potential Regulatory Approval for the Treatment of PSC with a Single, Clinical-Events-Driven Clinical Trial— — Th e se Major Mi...

More Chemomab Therapeutics Ltd - ADR News

Company Profile

Chemomab Therapeutics Ltd. operates as a clinical-stage biotech company. It discovers and develops therapeutics for conditions with unmet need that involve Inflammation and fibrosis. The company was founded by Adi Mor on September 22, 2011 and is headquartered in Tel Aviv, Israel.

Head office	United States
CEO	Adi Mor
Employees	20
Founded	2011
Website	www.chemomab.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now